Engineers Gate Manager’s Unity Biotechnology UBX Stock Holding History

Engineers Gate Manager’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,179	Closed	-$32K	–	2319
2021 Q4	$32K	Buy	+2,179	New	+$47.6K	﹤0.01%	1908
2021 Q1	–	Sell	-1,031	Closed	-$54K	–	2141
2020 Q4	$54K	Buy	+1,031	New	+$49.7K	﹤0.01%	1630

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Engineers Gate Manager's UBX Position: Q1 2022 in Review

Engineers Gate Manager sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 2,179 shares — an estimated $32K sold.

Engineers Gate Manager first reported a position in UBX in Q4 2020 and held it in 2 quarters. The position peaked at $54K in Q4 2020. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

Engineers Gate Manager reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
Engineers Gate Manager sold 2,179 Unity Biotechnology shares in Q1 2022, an estimated $32K.
Engineers Gate Manager first reported a position in Unity Biotechnology in Q4 2020 and held it in 2 quarters.
Engineers Gate Manager's Unity Biotechnology position peaked at $54K in Q4 2020.
70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on Engineers Gate Manager's 13F filing for Q1 2022, filed 16 May 2022.